- Home
- REPX vs SVRA Comparison
REPX vs SVRA Comparison
Compare REPX & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- SVRA
- Stock Information
- Founded
- REPX 2016
- SVRA 2007
- Country
- REPX United States
- SVRA United States
- Employees
- REPX N/A
- SVRA N/A
- Industry
- REPX Oil & Gas Production
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- REPX Energy
- SVRA Health Care
- Exchange
- REPX Nasdaq
- SVRA Nasdaq
- Market Cap
- REPX 581.0M
- SVRA 527.2M
- IPO Year
- REPX N/A
- SVRA N/A
- Fundamental
- Price
- REPX $26.06
- SVRA $4.38
- Analyst Decision
- REPX Strong Buy
- SVRA Buy
- Analyst Count
- REPX 2
- SVRA 8
- Target Price
- REPX $41.50
- SVRA $6.88
- AVG Volume (30 Days)
- REPX 133.1K
- SVRA 1.6M
- Earning Date
- REPX 11-05-2025
- SVRA 11-13-2025
- Dividend Yield
- REPX 5.88%
- SVRA N/A
- EPS Growth
- REPX N/A
- SVRA N/A
- EPS
- REPX 4.52
- SVRA N/A
- Revenue
- REPX $392,885,000.00
- SVRA N/A
- Revenue This Year
- REPX N/A
- SVRA N/A
- Revenue Next Year
- REPX $8.97
- SVRA N/A
- P/E Ratio
- REPX $5.72
- SVRA N/A
- Revenue Growth
- REPX N/A
- SVRA N/A
- 52 Week Low
- REPX $21.98
- SVRA $1.89
- 52 Week High
- REPX $37.55
- SVRA $4.51
- Technical
- Relative Strength Index (RSI)
- REPX 42.11
- SVRA 74.44
- Support Level
- REPX $25.85
- SVRA $4.15
- Resistance Level
- REPX $26.86
- SVRA $4.51
- Average True Range (ATR)
- REPX 0.79
- SVRA 0.23
- MACD
- REPX -0.12
- SVRA 0.04
- Stochastic Oscillator
- REPX 14.96
- SVRA 88.71
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.